Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control.
about
Interactions between kidney disease and diabetes: dangerous liaisonsAlternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitolLow levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes.Comparative associations of diabetes risk factors with five measures of hyperglycemia.Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management.Association of 1,5-anhydroglucitol with diabetes and microvascular conditions.1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions.Plasma metabolite biomarkers for the detection of pancreatic cancerThe interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoringRelationship between postprandial glucose level and carotid artery stiffness in patients without diabetes or cardiovascular disease.Racial Differences in and Prognostic Value of Biomarkers of Hyperglycemia.Measurement of 1,5-anhydroglucitol in blood and saliva: from non-targeted metabolomics to biochemical assay1,5-Anhydro-D-Glucitol Could Reflect Hypoglycemia Risk in Patients with Type 2 Diabetes Receiving Insulin Therapy.Relationship of glycemic control markers - 1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance.1,5-Anhydroglucitol in diabetes mellitus.Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?A computational model of 1,5-AG dynamics during pregnancy.1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes.Novel biomarkers for prediabetes, diabetes, and associated complications.Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular DiseasePlasma anhydro-D-glucitol (1,5-AG) as an indicator of hyperglycaemic excursions in pregnant women with diabetes.Metabolomics reveal mitochondrial and fatty acid metabolism disorders that contribute to the development of DKD in T2DM patients.High fasting insulin concentrations may be a pivotal predictor for the severity of hepatic fibrosis beyond the glycemic status in non-alcoholic fatty liver disease patients before development of diabetes mellitus.Metabolome analysis for pancreatic cancer risk in nested case-control study: Japan Public Health Center-based prospective Study.
P2860
Q26740630-10BA9230-742E-4458-816A-6FED150B6C98Q26801852-CFA9DAAB-D39E-49F8-BC10-BD909CC4E4A2Q33784296-D14F257B-3A91-41DB-93CE-63A42E0C5ADCQ34419206-A7A9A969-555A-4BAE-B406-42AB1E27586DQ34425731-88741D64-158A-4922-A8FE-5EDF81C30E77Q34433155-3692118C-F0CB-4449-AEE9-D9ABC3DD2E1EQ34726941-DC24341F-A146-4217-8D62-A475D63DD60AQ35072866-7ED8280D-9223-4F46-AD9F-567680B9A9EAQ35349795-60D4E3FD-85C9-4998-9DE8-2405224B6B8AQ36686926-75D017D8-8B1F-4141-9F93-F93F0650AE83Q36726169-F42F0457-F97B-4750-90E2-56A34B10207BQ36911219-90F3A082-80E3-4DFA-9BDC-965BD99A3C5EQ37043631-892A0C65-4709-49EB-9F34-8FA55E2E548DQ37292095-3579242D-BA7C-4605-BD17-F1AD46244DD8Q38030840-5A475FC2-9404-4006-A4CB-360E2FED6540Q38182542-7A93E8CC-A78B-4CD5-9719-A974AD85BC43Q38618027-A63BE7F0-4305-4F71-BBEA-995CC4F122C3Q39996202-BE8F8030-69F8-452E-AB5B-691259842A9EQ41475816-80B22DB2-77A8-4680-8282-99578FCB1D59Q41640157-D47C6458-33C5-49A0-8A66-EDE155370DFBQ46909184-17727D56-1236-46CA-9F11-B13879FE608AQ47733127-C354B7AB-BF0C-4D42-95EB-DE44BD668248Q47963224-9B38428D-9E1D-46EE-846D-9979624E2C2FQ52633517-19F0B121-E272-4D5A-8C6D-4581D5F92AF2
P2860
Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control.
@en
type
label
Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control.
@en
prefLabel
Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control.
@en
P1476
Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control.
@en
P2093
T Yamanouchi
P304
P356
10.1016/0168-8227(94)90259-3
P478
P577
1994-10-01T00:00:00Z